Antibodies, cancer therapy

Tyrosine kinase inhibitors Antibody Cancer therapy... 

Besides the hormone therapy, the notion of targeted cancer therapy is not so new and can be traced back to the 1940 s [2]. Early approaches included the largely unsuccessful use of antibodies, often conjugated with radioisotopes or toxins, directed against tumor-associated antigens. 

Targeted Cancer Therapy. Table 2 Main differences between monoclonal antibodies and small-molecule tyrosine kinase inhibitors... 

With the great diversity of targeted toxic agents being developed for cancer therapy, it would be difficult to characterize this section strictly as antibody conjugation. While many,... 

Colloidal gold-labeled (strept)avidin can be used as highly sensitive detection reagents for microscopy techniques (Cubie and Norval, 1989) (Chapter 24). Finally, cytotoxic substances coupled to (strept)avidin can be used to direct cell-killing activity toward a tumor-cell-bound, biotinylated monoclonal antibody (or other targeting molecule) for cancer therapy (Hashimoto et al, 1984) (Chapter 21). 

Patri, A.K., Myc, A., Beals, J., Thomas, T.P., Bander, N.H., and Baker Jr., J.R. (2004) Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate Chem. 15, 1174-1181. 

Reisfeld, R.A., Yang, H.M., Mullet B., Wargalla, U.C., Schrappe, M., and Wrasidlo, W. (1989) Promises, problems, and prospects of monoclonal antibody-drug conjugates for cancer therapy. Antibody, Immunoconjugates, Radiopharm. 2, 217-224. 

Human carcinoembryonic antigen Mouse/human chimeric IgGl antibody (cT84.66) Antibody - mediated cancer therapy (colon cancer, breast cancer and tumor with epithelial origin) N. tabacum cv petit Havana SRI (Transient expression) 35S MSP + 1 mg/kg FLW 42... 

Colon cancer surface antigen CO-17A IgG Antibody - mediated cancer therapy N. benthamiana MSP 49... 

In summary, TSA-based complications in the context of developing antibody-based cancer therapies include ... 

Eisenstein, T. (ed.). 2003. Hepatitis B, the Virus, the Disease and the Vaccine. Kluwer. Grossbard, M. 1998. Monoclonal Antibody Based Therapy of Cancer. Dekker. 

Oldham, R.K. (1983). Monoclonal antibodies in cancer therapy. J. Clin. Oncol. 1 582-590. 

Funaro A, Florenstein AL, Santoro P, et al. Monoclonal antibodies and therapy of human cancers. Biotechnology Advances 18 385-401 (2000). 

Hudson PJ. Recombinant antibody constructs in cancer therapy. Current Opinion in Immunology 11 548-557 (1999). 

Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy, Drug Development Research 61 172-187 (2004). 

Whereas initially the focus on antibody-based therapies was on cancer, anti-TNFa antibodies in particular have recently proven powerful in the therapy of chronic inflammatory diseases such as inflammatory bowel disease and rhemnatoid arthritis [71], These antibodies complex serum TNFa, the clinical benefit to RA patients most likely being the reduction of pro-inflammatory IL-6 and acute phase protein levels [9], Although they are directed against soluble proteins and as such will not serve as a drug carrier, they do show that targeted, i.e. selective, interference with a specific molecule or process can have a powerful effect without significant concomitant toxicity. 

The ground-breaking development of monoclonal antibodies by Kohler and Milstein [21] initiated the development of antibody-mediated therapeutics for cancer. Because of their unique specificity, MAb were predicted to become the magic bullets in the battle against cancer. Over the last two and a half decades MAbs have moved from clone to clinic for the treatment of various malignancies. Several MAbs are currently entering clinical trials and should appear on the market in the next few years. The first MAb for cancer therapy was approved in the US in 1997. 

Table 8.6. Monoclonal antibody based products and liposome formulations registered for cancer therapy in the USA and/or Europe.

Saleh MN, LoBuglio AF, Trail PA, In Monoclonal Antibody-Based Therapy of Cancer (Ed. Grossband M), pp. 397 16. Marcel Dekker, New York, 1998. 

Kasprzyk, P. G., S. U. Song, P. P. Di Fiore, and C. R. King. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res, 52 2771-2776.1992. 

---